COMMUNIQUÉS West-GlobeNewswire

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
23/12/2024
– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company [...]
XBiotech Pauses Rheumatology program
23/12/2024
Findings from recently completed Rheumatoid Arthritis Study raise questions AUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data that it is halting its clinical program in [...]
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
23/12/2024
LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ [...]
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
23/12/2024
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic [...]
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
23/12/2024
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to [...]
Nova Leap Health Corp. Grants Stock Options
23/12/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 23, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
23/12/2024
THE WOODLANDS, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how [...]
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
23/12/2024
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual [...]
Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial
23/12/2024
Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel ® Precision Radionuclide Therapy™ in India. This milestone trial [...]
Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share
23/12/2024
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC) (“Singular Genomics” or the “Company”), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics [...]
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
23/12/2024
In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & gene fusion [...]
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
23/12/2024
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to [...]
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
23/12/2024
Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE NEWSWIRE) -- HCW [...]
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
23/12/2024
CORXEL expands its cardiometabolic pipeline into obesity and diabetes NEW JERSEY and SHANGHAI, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing [...]
Spectral AI Announces Confirmation of Compliance of its Nasdaq Listing Requirements
23/12/2024
DALLAS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. FDA in [...]
Signati™ Medical Successfully Completes IDE Trial for Separo™ Vessel Sealing System and Initiates FDA Market Clearance Process
23/12/2024
Providence, RI, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Signati™ Medical is proud to announce the successful completion of its Investigational Device Exemption (IDE) trial evaluating the Separo™ Vessel Sealing System for [...]
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
23/12/2024
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members [...]
Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs
23/12/2024
Patent for methods of use of topical DNase enzymes in the eye covers L304, Neutrolis’ proprietary therapy in development for the treatment of moderate to severe dry eye disease CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE [...]
Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia
23/12/2024
Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA [...]

Pages